Neurocrine Biosciences, Inc. (NBIX)

101.26
0.58 0.57
NASDAQ
Prev Close 101.84
Open 101.61
Day Low/High 100.51 / 102.37
52 Wk Low/High 84.77 / 120.27
Volume 338.41K
Exchange NASDAQ
Shares Outstanding 94.65B
Market Cap 9.71B
P/E Ratio 120.53
Div & Yield N.A. (N.A)

Latest News

Spring Cleaning: Let's Tidy Up Some Trades

Spring Cleaning: Let's Tidy Up Some Trades

Not every trade can be a winner, so let's lighten the load here.

A Bullish Play on Neurocrine Biosciences

A Bullish Play on Neurocrine Biosciences

Analysts weren't shy to defend the company after Tuesday's earnings.

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

A roundup of biotech names with actions pending at the FDA in coming weeks.

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Technology and biotech companies seem to be among the big winners.

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.

2 Biotech Pullback Targets

2 Biotech Pullback Targets

Acadia and Neurocrine both have catalysts for growth; buy any weakness.

Neurocrine Bio upgraded at Oppenheimer

Another Biotech Play

Another Biotech Play

Keep this one on the radar for a pullback buying opportunity.